Alex Zhavoronkov, PhD
CEO of InSilico Medicine, USA
Dr. Alex Zhavoronkov is the founder and CEO of InSilico Medicine, a global leader in the next-generation artificial intelligence technologies for drug discovery, biomarker development, and aging research. At InSilico, he pioneered the applications of generative adversarial networks and reinforcement learning techniques for generating the novel molecular structures with the desired properties and generation of synthetic biological and patient data. His group was the first to develop the deep-learned multi-modal predictors of age for drug discovery and biomarker development. He set up the R&D centers in 6 countries, including the United Kingdom, Korea, Russia, Hong Kong SAR, and Taiwan ROC.
Prior to founding InSilico Medicine, Dr. Zhavoronkov worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, and YLabs.AI and established the AgeNet.net competitions and Diversity.AI initiatives. He is co-founder and CSO of the Biogerontology Research Foundation (BGRF), a registered UK charity focusing on age-related diseases.
Since 2012, Dr. Zhavoronkov published over 120 peer-reviewed research papers and 2 books, including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). From 2014 to 2018, he presented at over 200 academic and industry conferences.
Dr. Zhavoronkov serves on the editorial boards of some of the highest-impact journals in the field, including Aging, Aging Research Reviews, Frontiers in Genetics of Aging, Trends in Molecular Medicine, and chairs the Annual Aging Research for Drug Discovery Forum (6th annual in 2019) at the Basel Life. Dr. Zhavoronkov holds two bachelor degrees from Queen’s University, a master’s in Biotechnology from Johns Hopkins University, and a PhD in Physics and Mathematics from Moscow State University. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.